REGULATORY DOSE

The price of cardiac stents: It is industry against civil society once more

Pharmaceutical bodies want innovation products to be left out of price control but doctors' association want prices of all stents to be regulated.

In an attempt to make life-saving cardiac stents more affordable, the National Pharmaceutical Pricing Authority or NPPA has proposed fixing prices ranging between Rs 21,881 and Rs 67,272. The price of stents, which are tiny devices used to unblock diseases arteries, currently starts at Rs 23,000 and goes up to as much as Rs 2.5 lakh per piece.

The NPPA’s moves on cardiac stents have been watched closely by manufacturers, doctors and health activists, ever since the authority announced on January 2 that it would not use the formula it normally uses to cap drug prices. As per procedure set out in Drug Price Control Orders, the authority usually sets a ceiling price by averaging the retail prices of drugs that have at least 1% of the market share each and marking it up by 16% for the retailer.

However, considering that stents are sold by hospitals at varying prices and, often at outrageous profits, the NPPA has come up with different formulae that do not consider the maximum retail price as the base price.

One formula being considered for calculating the ceiling price is based on the price of the device to distributor. Another includes the landed cost, with reference to imported devices, and accounts for manufacturing, shipping, and customs duties. Another formula is based on the cost of production or the cost of the stent under Central Government Health Scheme that amounts to Rs 23,675.

The Medical Devices Forum of the Federation of Indian Chambers of Commerce, which largely represents companies manufacturing foreign stents, had made a representation to the NPPA asking for price to hospital to be the base for calculations. The price to hospital is a much higher base price, because it includes the profit margins of the distributor. On January 4, the NPPA added price to hospital as a possible base price to fix the ceiling price.

As expected, when the NPPA calculated ceiling prices using these different starting points, the price calculated using “price to hospital” was the highest at Rs 67,272.

In the next one month while the NPPA finalises the ceiling price for stents, stakeholders like pharmaceutical companies, doctors and civil society will lobby before the authority to protect interests of either the industry or patients, depending on where they stand.

Different kinds of stents

A stent is a short wire mesh tube that acts as a scaffold to keep a previously blocked artery of the heart open. A bare metal stent is an older generation device that consists only of the scaffolding. The newer drug-eluting stent has a coat of medicine, which it releases in the artery after its insertion. The drug prevents further blockage in the artery of the heart. More than 2 lakh stents are used annually, of which drug-eluting stents constitute 78%.

The NPPA has, so far, decided to fix prices based on these two categories – bare metal and drug-eluting

However, FICCI is asking that the authority take note of further differentiation in drug-eluting like drug-eluting stents used in the majority of cardiovascular procedures, drug-eluting stents for highly complex disease subsets including diabetes, and innovative drug-eluting stents. The innovative category, FICCI said, should not be covered by Drug Price Control Order.

“If the prices for all the drug-eluting stents remain the same, then only the older generation stents will be brought to the country,” said Probir Das, chairman of the FICCI’s Medical Devices Forum. “The newer, more sophisticated ones will not come to India.”

The newer generation stents are better, Das said, because they reduce chances of re-stenosis, which is when the blood vessel becomes blocked again.

Alliance of Doctors for Ethical Healthcare met the National Pharmaceutical Pricing Authority last week.
Alliance of Doctors for Ethical Healthcare met the National Pharmaceutical Pricing Authority last week.

The views of cardiologists in the private sector is aligned with the foreign manufacturers.

However, a report submitted by a committee of doctors from the public hospitals across India on the essentiality of coronary stents noted that there is no superiority among the current available drug-eluting stents in terms of clinical outcomes deaths or heart attacks. The committee also said that the superiority of bio-absorbable stents, a new type of stent that dissolves in the body, has not been demonstrated yet.

A study published in November 2016 in the journal Lancet showed that bio-absorbable stents, which are classified as innovative products by FICCI, posed “increased risk” of artery blockage. Other studies show bypass surgeries that do not require stents work better for diabetic patients as compared to angioplasties that are the procedures to place stents. Despite this research, FICCI has demanded a separate category for disease subsets to allow higher pricing of innovative stents that may not always be effective.

However, the Association of Indian Medical Device Industry does not support differential pricing of stents. “We are aligned with the consumer,” said Rajiv Nath, co-ordinator of the association.

Deciding the baseline

Currently, the various stakeholders are fighting to be heard on pricing by the NPPA. Civil society groups such as All India Drug Action Network, Jan Swasthya Abhiyan, and the Alliance of Doctors for Ethical Healthcare are happy with the formula based on the Central Government Health Scheme that throws up the lowest price.

The “price to hospital” formula is with the NPPA itself saying that hospital data is not reliable as the prices change continuously.

Malini Aisola from the All India Drug Action Network said, “The data shows very clearly that the “price-to-hospital” formula is unworkable and does not serve the purpose of affordability. Public policy involving people’s health should not be predicated upon non-verifiable, inflated industry data. The industry itself has admitted that it has imperfect knowledge of the actual price. Government and political leadership should not legitimise the exploitation of the people.”

But the FICCI body wants hospitals at least have their say before any decision is made. “A retailer just dispenses with the product,” said Das. “A hospital is deploying and implanting the product. It also creates a cathlab which costs at least Rs 2 crore. It also maintains an inventory,” said Das. Cathlab is short for catheterisation laboratory where diagnostic imaging equipment is used to visualise the heart and its arteries.

When pointed out that hospitals charge for implanting stents, Das said that if stent prices fall, hospitals will compensate by raising costs of the medical procedure.

Fixing the price of stents can end another unethical practice. It is an open secret that the hospitals demand a cut from the pharmaceutical companies for using devices, which leads to irrational use of stents. Dr Anil Kumar Pathak from the Alliance of Doctors for Ethical Healthcare recounted a case of a patient in his late 30s who was implanted with the stent, even though he had only 50% blockage in his arteries and did not need one.

“The fixing of the price will increase the rational use of stents,” said Dr Arun Mitra, also a member of the alliance. “The cuts have so far encouraged doctors to implant stents when it was not required.”

We welcome your comments at letters@scroll.in.
Sponsored Content BY 

What hospitals can do to drive entrepreneurship and enhance patient experience

Hospitals can perform better by partnering with entrepreneurs and encouraging a culture of intrapreneurship focused on customer centricity.

At the Emory University Hospital in Atlanta, visitors don’t have to worry about navigating their way across the complex hospital premises. All they need to do is download wayfinding tools from the installed digital signage onto their smartphone and get step by step directions. Other hospitals have digital signage in surgical waiting rooms that share surgery updates with the anxious families waiting outside, or offer general information to visitors in waiting rooms. Many others use digital registration tools to reduce check-in time or have Smart TVs in patient rooms that serve educational and anxiety alleviating content.

Most of these tech enabled solutions have emerged as hospitals look for better ways to enhance patient experience – one of the top criteria in evaluating hospital performance. Patient experience accounts for 25% of a hospital’s Value-Based Purchasing (VBP) score as per the US government’s Centres for Medicare and Mediaid Services (CMS) programme. As a Mckinsey report says, hospitals need to break down a patient’s journey into various aspects, clinical and non-clinical, and seek ways of improving every touch point in the journey. As hospitals also need to focus on delivering quality healthcare, they are increasingly collaborating with entrepreneurs who offer such patient centric solutions or encouraging innovative intrapreneurship within the organization.

At the Hospital Leadership Summit hosted by Abbott, some of the speakers from diverse industry backgrounds brought up the role of entrepreneurship in order to deliver on patient experience.

Getting the best from collaborations

Speakers such as Dr Naresh Trehan, Chairman and Managing Director - Medanta Hospitals, and Meena Ganesh, CEO and MD - Portea Medical, who spoke at the panel discussion on “Are we fit for the world of new consumers?”, highlighted the importance of collaborating with entrepreneurs to fill the gaps in the patient experience eco system. As Dr Trehan says, “As healthcare service providers we are too steeped in our own work. So even though we may realize there are gaps in customer experience delivery, we don’t want to get distracted from our core job, which is healthcare delivery. We would rather leave the job of filling those gaps to an outsider who can do it well.”

Meena Ganesh shares a similar view when she says that entrepreneurs offer an outsider’s fresh perspective on the existing gaps in healthcare. They are therefore better equipped to offer disruptive technology solutions that put the customer right at the center. Her own venture, Portea Medical, was born out of a need in the hitherto unaddressed area of patient experience – quality home care.

There are enough examples of hospitals that have gained significantly by partnering with or investing in such ventures. For example, the Children’s Medical Centre in Dallas actively invests in tech startups to offer better care to its patients. One such startup produces sensors smaller than a grain of sand, that can be embedded in pills to alert caregivers if a medication has been taken or not. Another app delivers care givers at customers’ door step for check-ups. Providence St Joseph’s Health, that has medical centres across the U.S., has invested in a range of startups that address different patient needs – from patient feedback and wearable monitoring devices to remote video interpretation and surgical blood loss monitoring. UNC Hospital in North Carolina uses a change management platform developed by a startup in order to improve patient experience at its Emergency and Dermatology departments. The platform essentially comes with a friendly and non-intrusive way to gather patient feedback.

When intrapreneurship can lead to patient centric innovation

Hospitals can also encourage a culture of intrapreneurship within the organization. According to Meena Ganesh, this would mean building a ‘listening organization’ because as she says, listening and being open to new ideas leads to innovation. Santosh Desai, MD& CEO - Future Brands Ltd, who was also part of the panel discussion, feels that most innovations are a result of looking at “large cultural shifts, outside the frame of narrow business”. So hospitals will need to encourage enterprising professionals in the organization to observe behavior trends as part of the ideation process. Also, as Dr Ram Narain, Executive Director, Kokilaben Dhirubhai Ambani Hospital, points out, they will need to tell the employees who have the potential to drive innovative initiatives, “Do not fail, but if you fail, we still back you.” Innovative companies such as Google actively follow this practice, allowing employees to pick projects they are passionate about and work on them to deliver fresh solutions.

Realizing the need to encourage new ideas among employees to enhance patient experience, many healthcare enterprises are instituting innovative strategies. Henry Ford System, for example, began a system of rewarding great employee ideas. One internal contest was around clinical applications for wearable technology. The incentive was particularly attractive – a cash prize of $ 10,000 to the winners. Not surprisingly, the employees came up with some very innovative ideas that included: a system to record mobility of acute care patients through wearable trackers, health reminder system for elderly patients and mobile game interface with activity trackers to encourage children towards exercising. The employees admitted later that the exercise was so interesting that they would have participated in it even without a cash prize incentive.

Another example is Penn Medicine in Philadelphia which launched an ‘innovation tournament’ across the organization as part of its efforts to improve patient care. Participants worked with professors from Wharton Business School to prepare for the ideas challenge. More than 1,750 ideas were submitted by 1,400 participants, out of which 10 were selected. The focus was on getting ideas around the front end and some of the submitted ideas included:

  • Check-out management: Exclusive waiting rooms with TV, Internet and other facilities for patients waiting to be discharged so as to reduce space congestion and make their waiting time more comfortable.
  • Space for emotional privacy: An exclusive and friendly space for individuals and families to mourn the loss of dear ones in private.
  • Online patient organizer: A web based app that helps first time patients prepare better for their appointment by providing check lists for documents, medicines, etc to be carried and giving information regarding the hospital navigation, the consulting doctor etc.
  • Help for non-English speakers: Iconography cards to help non-English speaking patients express themselves and seek help in case of emergencies or other situations.

As Arlen Meyers, MD, President and CEO of the Society of Physician Entrepreneurs, says in a report, although many good ideas come from the front line, physicians must also be encouraged to think innovatively about patient experience. An academic study also builds a strong case to encourage intrapreneurship among nurses. Given they comprise a large part of the front-line staff for healthcare delivery, nurses should also be given the freedom to create and design innovative systems for improving patient experience.

According to a Harvard Business Review article quoted in a university study, employees who have the potential to be intrapreneurs, show some marked characteristics. These include a sense of ownership, perseverance, emotional intelligence and the ability to look at the big picture along with the desire, and ideas, to improve it. But trust and support of the management is essential to bringing out and taking the ideas forward.

Creating an environment conducive to innovation is the first step to bringing about innovation-driven outcomes. These were just some of the insights on healthcare management gleaned from the Hospital Leadership Summit hosted by Abbott. In over 150 countries, Abbott, which is among the top 100 global innovator companies, is working with hospitals and healthcare professionals to improve the quality of health services.

To read more content on best practices for hospital leaders, visit Abbott’s Bringing Health to Life portal here.

This article was produced on behalf of Abbott by the Scroll.in marketing team and not by the Scroll.in editorial staff.